Details of the SBP
General Information of Synthetic Binding Protein (SBP) (ID: SBP003368) | ||||||
---|---|---|---|---|---|---|
SBP Name |
Fab Abrezekimab
|
|||||
Synonyms |
VR 942; UCB4144
|
|||||
Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
Highest Status | Phase I | |||||
SBP Sequence |
>VH Chain
QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFN SVLKSRLTISRDTSKSQVVLTMTNMDPVATYYCARDGTIAAMDYFDYWGQGTLVTVSS >VL Chain DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCGYRFPLTFGGGTKVEIK |
|||||
Protein Scaffold Information of This SBP | ||||||
---|---|---|---|---|---|---|
Scaffold ID | PS034 | [1] | ||||
Scaffold Name | Fab | |||||
Scaffold Class | Antibody fragment | |||||
Fold Type | Beta-Sheets + Loops | |||||
Binding Target(s) of This SBP (BTS) |
---|
BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
---|---|---|---|---|---|---|
Interleukin-13 | Binder | Asthma [ICD-11: CA23] | N.A. | UCB Pharma; Vectura | [1] | |
Clinical Trial Information of This SBP | ||||||
---|---|---|---|---|---|---|
NCT02473939 | Click to show the Detail | |||||
Indication | Healthy Subjects and Repeated Doses in Mild Asthmatics | |||||
Phase | Phase I | |||||
Title | A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics | |||||
Status | Completed | |||||
Sponsor | Vectura Limited | |||||